An open-label, single-center, phase 1/2 study of chemoradiotherapy and AT-101 in patients with locally advanced esophageal or gastroesophageal junction cancer (AT-101-CS-102).
Latest Information Update: 24 Aug 2011
At a glance
- Drugs AT 101 (Primary) ; Docetaxel; Fluorouracil
- Indications Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ascenta Therapeutics
- 18 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
- 01 Jan 2011 Status changed from active, no longer recruiting to recruiting as reported by M.D. Anderson Cancer Center record.
- 30 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center record.